Skip to Main Content

Paper Details

Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.
Clin Drug Investig
3
2022
Author NameAffiliation
Maria Del ZompoUniversity of Cagliari
Mirko ManchiaUniversity of Cagliari
Mirko ManchiaUnit of Clinical Psychiatry, University Hospital Agency of Cagliari
Mirko ManchiaDalhousie University
Alessio SquassinaUniversity of Cagliari
  • 1 - 5

Datasets

Release 1.2